The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes.

Published in: Diabetes, obesity & metabolism (2024)

) in a subsequent larger study.

Keyphrases